From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat. ?
Legal status ?
Routes ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half-life ?
Excretion ?
CAS number 54-92-2 YesY
ATC code N06AF05
PubChem CID 3748
DrugBank DB04818
ChemSpider 3617 YesY
KEGG D02579 YesY
Chemical data
Formula C9H13N3O 
Mol. mass 179.219
 YesY (what is this?)  (verify)

Iproniazid (Euphozid, Iprazid, Ipronid, Ipronin, Marsilid, Rivivol) is a hydrazine drug used as an antidepressant.[1] It acts as an irreversible and nonselective monoamine oxidase inhibitor (MAOI).[2] Though it has been widely discontinued in most of the world, it is still used in France. As with all MAOIs, iproniazid is contraindicated in patients using SSRIs, SRAs, and serotonin agonists.


Iproniazid was the first antidepressant ever marketed. Originally intended for the treatment of tuberculosis.[1] In 1952, its antidepressant properties were discovered when researchers noted that the patients given iproniazid became "inappropriately happy".[1] Subsequently N-isopropyl addition lead to development as an antidepressant and was approved for use in 1958.[1] It was later withdrawn in 1961 due to the unacceptable incidence of hepatitis and was replaced by less hepatotoxic drugs like isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate).[1]

See also[edit]


  1. ^ a b c d e Robert A. Maxwell, Shohreh B. Eckhardt (1990). Drug discovery. Humana Press. pp. 143–154. ISBN 0-89603-180-2. ISBN 9780896031807. 
  2. ^ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical pharmacology 35 (8): 1381–7. doi:10.1016/0006-2952(86)90285-6. PMID 2870717.